2100-31-4Relevant articles and documents
A NANOSPHERE - HISTONE ACETYLTRANSFERASE (HAT) ACTIVATOR COMPOSITION, PROCESS AND METHODS THEREOF
-
Page/Page column 16, (2013/11/18)
The present disclosure is in relation to a composition comprising nanosphere and histone acetyltransferase (HAT) activator. The disclosed nanosphere is carbon nanosphere (CSP) which is intrinsically fluorescent and the HAT activator is N-(4-Chloro-3-trifluoromethyl- phenyl)-2-n-propoxy-benzamide [COMPOUND 1]. The said N-(4-Chloro-3-trifluoromethyl- phenyl)-2-n-propoxy-benzamide is covalently conjugated with the carbon nanosphere. The present disclosure further relates to a process for obtaining a composition comprising carbon nanosphere and Histone acetyltransferase (HAT) activator [N-(4-Chloro-3-trifluoromethyl- phenyl)-2-n-propoxy-benzamide]. The composition is capable of crossing blood brain barrier and inducing histone acetylation in brain. Further, the composition is capable of increasing neurogenesis, as well as improving long-term memory formation. The said composition thus provides for managing pathological conditions to a subject in need thereof, such as aging- related, neurodegenerative diseases (Alzheimer's in particular), neurological disorders, depression or other kinds of diseases in which increased HAT activity, neurogenesis and/or memory improvement would benefit.
ALLYLQXY AND ALKYLOXY BENZOIC ACID DELIVERY AGENTS
-
Page/Page column 41, (2008/12/07)
The present invention relates to pharmaceutical compounds for delivering active agents, such as biologically or chemically active agents, to a target. The invention also relates to pharmaceutical compositions comprising at least one delivery agent compound of the present invention and at least one active agent, and unit dosage forms comprising such compositions. Methods for the preparation and administration of the pharmaceutical compositions are also disclosed.
Quinazolinone inhibitors of cGMP phosphodiesterase
-
, (2008/06/13)
Novel quinazolinone compounds, methods of using such compounds in the treatment of cGMP-associated conditions such as erectile dysfunction, and pharmaceutical compositions containing such compounds.